Royalty Pharma (RPRX) Price & Analysis

Compare

1,292 Followers

RPRX Stock Chart & Stats

$40.02

$0.10(0.38%)

At close: Jan 08 4:00 PM EST

$40.02

$0.10(0.38%)

Day’s Range― - ―

52-Week Range$24.05 - $41.24

Previous CloseN/A

Volume726.99K

Average Volume (3M)3.73M

Market Cap

$23.10B

Enterprise Value$30.96B

Total Cash (Recent Filing)$955.04M

Total Debt (Recent Filing)$8.97B

Price to Earnings (P/E)22.9

Beta0.17

Next Earnings

Feb 17, 2026

EPS Estimate

1.27

Last Dividend Ex-Date

Nov 14, 2025

Dividend Yield2.2%

Share Statistics

EPS (TTM)1.17

Shares Outstanding427,247,500

10 Day Avg. Volume3,427,263

30 Day Avg. Volume3,729,909

Financial Highlights & Ratios

PEG Ratio-0.55

Price to Book (P/B)1.64

Price to Sales (P/S)5.03

P/FCF Ratio4.11

Enterprise Value/Market Cap1.34

Enterprise Value/Revenue13.17

Enterprise Value/Gross Profit13.17

Enterprise Value/Ebitda19.55

Forecast

1Y Price Target

$43.80

Price Target Upside9.45% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering6

EPS Forecast (FY)4.56

Revenue Forecast (FY)$2.99B

Bulls Say, Bears Say

Bulls Say

Growth PotentialRPRX is in the early stages of a multi-year portfolio expansion that is underappreciated in the context of a large, growing market for royalty funding, with additional potential tailwinds from China biotech innovation trends.

Portfolio ExposureRPRX represents a unique vehicle through which generalist portfolio managers can gain exposure to a highly curated portfolio of biopharma royalty streams without incurring biotech’s volatility and binary risks.

Revenue GrowthRPRX's total royalty receipts, a proxy for the company's topline, are expected to grow significantly, representing a compound annual growth rate of 8.7%.

Bears Say

Royalty Pharma News

Royalty Pharma downgraded to Hold from Buy at TD Cowen

TD Cowen downgraded Royalty Pharma (RPRX) to Hold from Buy without a price target after the company agreed...

15d ago

RPRX

Royalty Pharma 14.244M share Block Trade priced at $40.00

The deal priced below last closing price of $40.78. Morgan Stanley is acting as sole book running manager...

24d ago

RPRX

Royalty Pharma 14.244M share Block Trade; price range $40.00-$40.78

Morgan Stanley is acting as sole book running manager for the offering. Published first on TheFly – the...

25d ago

RPRX

Royalty Pharma reports Q3 portfolio receipts of $814M

“We delivered strong third quarter 2025 results, raised our full year guidance and are on track to deliver...

27d ago

RPRX

Royalty Pharma raises FY25 portfolio receipts view to $3.2B-$3.25B

Royalty Pharma (RPRX) expects 2025 Portfolio Receipts to be between $3,200 million and $3,250 million, previously $3,050 million...

27d ago

RPRX

Royalty Pharma acquires royalty interest in Alnylam’s AMVUTTRA for $310M

Royalty Pharma (RPRX) announced that it has acquired a royalty interest in Alnylam’s AMVUTTRA from funds managed by...

28d ago

RPRX

Royalty Pharma Reports Strong Q3 2025 Results

Royalty Pharma PLC ( ($RPRX) ) has released its Q3 earnings. Here is a breakdown of the information...

26d ago

RPRX

Royalty Pharma’s Q3 2025 Earnings Call Highlights

Royalty Pharma PLC (($RPRX)) has held its Q3 earnings call. Read on for the main highlights of the...

26d ago

RPRX

Royalty Pharma price target lowered to $54 from $55 at Morgan Stanley

Morgan Stanley analyst Terence Flynn lowered the firm’s price target on Royalty Pharma (RPRX) to $54 from $55...

2M ago

RPRX

Royalty Pharma: Strategic Positioning and Growth Potential Drive Buy Rating

Royalty Pharma (RPRX) has received a new Buy rating, initiated by Goldman Sachs analyst, Asad Haider. Asad Haider...

2M ago

RPRX

Royalty Pharma initiated with a Buy at Goldman Sachs

Goldman Sachs initiated coverage of Royalty Pharma (RPRX) with a Buy rating and $42 price target which represents...

2M ago

RPRX

Royalty Pharma appoints Ted Love as lead independent director

Royalty Pharma (RPRX) announced that the independent directors of the Board have unanimously appointed Dr. Ted W. Love,...

2M ago

RPRX

These 3 “Strong Buy” Value Stocks Have over 30% Upside, According to Analysts – 9/17/2025

Value stocks offer stability for investors by focusing on companies that seem underpriced compared to their actual worth....

2M ago

DOX

ZTO

Royalty Pharma Completes $2 Billion Senior Notes Offering

Royalty Pharma ( ($RPRX) ) has issued an announcement. On September 16, 2025, Royalty Pharma plc successfully completed...

3M ago

RPRX

RPRX FAQ

What was Royalty Pharma PLC’s price range in the past 12 months?

Royalty Pharma PLC lowest stock price was $24.05 and its highest was $41.24 in the past 12 months.

What is Royalty Pharma PLC’s market cap?

Royalty Pharma PLC’s market cap is $23.10B.

When is Royalty Pharma PLC’s upcoming earnings report date?

Royalty Pharma PLC’s upcoming earnings report date is Feb 17, 2026 which is in 77 days.

How were Royalty Pharma PLC’s earnings last quarter?

Royalty Pharma PLC released its earnings results on Nov 05, 2025. The company reported $1.173 earnings per share for the quarter, beating the consensus estimate of $0.994 by $0.179.

Is Royalty Pharma PLC overvalued?

According to Wall Street analysts Royalty Pharma PLC’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Royalty Pharma PLC pay dividends?

Royalty Pharma PLC pays a Quarterly dividend of $0.22 which represents an annual dividend yield of 2.2%. See more information on Royalty Pharma PLC dividends here

What is Royalty Pharma PLC’s EPS estimate?

Royalty Pharma PLC’s EPS estimate is 1.27.

How many shares outstanding does Royalty Pharma PLC have?

Royalty Pharma PLC has 427,247,500 shares outstanding.

What happened to Royalty Pharma PLC’s price movement after its last earnings report?

Royalty Pharma PLC reported an EPS of $1.173 in its last earnings report, beating expectations of $0.994. Following the earnings report the stock price went up 6.83%.

Which hedge fund is a major shareholder of Royalty Pharma PLC?

Currently, no hedge funds are holding shares in RPRX

Royalty Pharma Stock Smart Score

Outperform

Fundamentals

Return on Equity

11.51%

Trailing 12-Months

Asset Growth

7.23%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Royalty Pharma PLC

Royalty Pharma (RPRX) is a leading acquirer of pharmaceutical royalties, focusing on innovative medicines across various therapeutic areas, including oncology, infectious diseases, and neurology. The company specializes in purchasing royalty interests from biopharmaceutical companies and investors, allowing them to monetize their future cash flows from approved drugs. By leveraging its expertise in drug development and commercialization, Royalty Pharma partners with a range of stakeholders in the pharmaceutical industry to maximize the value of their products.

Royalty Pharma (RPRX) Earnings & Revenues

Historic Earnings Reports

RPRX Company Deck

RPRX Earnings Call

Q3 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

Royalty Pharma reported a strong financial performance with significant growth and strategic acquisitions in the third quarter of 2025, leading to an upward revision of its full-year guidance. Despite challenges such as the upcoming decline in Promacta royalties and increased interest expenses, the company's diversified portfolio and pipeline expansion underline its growth potential.View all RPRX earnings summaries

RPRX Revenue Breakdown

93.34% Income from financial royalty assets

6.62% Other royalty income

0.04% Revenue from intangible royalty assets

RPRX Stock 12 Month Forecast

Average Price Target

$43.80

▲(9.45% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"23":"$23","31":"$31","39":"$39","47":"$47","55":"$55"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":54,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$54.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":43.8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$43.80</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":38,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$38.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[23,31,39,47,55],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,37.33,38.61230769230769,39.894615384615385,41.176923076923075,42.45923076923077,43.74153846153846,45.02384615384615,46.30615384615385,47.58846153846154,48.87076923076923,50.153076923076924,51.43538461538461,52.7176923076923,{"y":54,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,37.33,37.8276923076923,38.325384615384614,38.82307692307692,39.32076923076923,39.818461538461534,40.316153846153846,40.81384615384615,41.31153846153846,41.809230769230766,42.30692307692308,42.80461538461538,43.30230769230769,{"y":43.8,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,37.33,37.38153846153846,37.433076923076925,37.48461538461538,37.536153846153844,37.58769230769231,37.63923076923077,37.69076923076923,37.74230769230769,37.793846153846154,37.84538461538462,37.89692307692307,37.94846153846154,{"y":38,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":26.22,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.78,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.88,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.8,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.03,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.6,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.89,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.88,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.47,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.68,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.97,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.12,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.33,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >